Soleno Therapeutics Inc SLNO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SLNO is a good fit for your portfolio.
News
-
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
-
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
-
Soleno Therapeutics to Present at Upcoming February Investor Conferences
-
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
The best-performing stock of the year rose nearly 2,000%, while the second best averted disaster to log a tenfold gain in a wild 2023
Trading Information
- Previous Close Price
- $37.34
- Day Range
- $37.09–38.33
- 52-Week Range
- $3.16–53.82
- Bid/Ask
- $37.82 / $37.90
- Market Cap
- $1.27 Bil
- Volume/Avg
- 138,612 / 321,848
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 42
- Website
- https://www.soleno.life
Valuation
|
Metric
|
SLNO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.51 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SLNO
|
|---|---|
Quick Ratio | 14.75 |
Current Ratio | 14.89 |
Interest Coverage | — |
Quick Ratio
SLNO
Profitability
|
Metric
|
SLNO
|
|---|---|
Return on Assets (Normalized) | −46.93% |
Return on Equity (Normalized) | −73.12% |
Return on Invested Capital (Normalized) | −78.78% |
Return on Assets
SLNO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fsvgrlkfv | Tqn | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fbsddtq | Dcfnkrt | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jsjpwklpf | Dmltzt | $97.8 Bil | |
MRNA
| Moderna Inc | Pmxsrpq | Bgvf | $41.3 Bil | |
ARGX
| argenx SE ADR | Yznkmrwj | Jmv | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Symvqnnx | Yzlp | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xgxbcnz | Szgqlvg | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vxnxvkxll | Dxsqcp | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kyrjvsxyh | Nwlbby | $12.5 Bil | |
INCY
| Incyte Corp | Syhyhpczf | Xynzb | $11.6 Bil |